ELVN Company Profile and Key Details

ELVN has shown sold momentum, gaining 8.07% over the past week and 26.34% over the past quarter, though year-to-date performance is up 75.65%. Short-term trend indicators are bearishly aligned (SMA20 7.83%, SMA50 26.45%, SMA200 40.87%). The stock’s 14-day RSI is 66.44 (firm momentum), while the ATR of 1.58 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -1.99% below its high and over 122.71% above its low. Average 10-day trading volume of 1.49 million shares is slightly above the 3-month average of 1.09 million, indicating heightened recent market interest.

Enliven Therapeutics, Inc. generated EPS of -$1.85 over the past year. Five-year average earnings growth is 19.02%. Wall Street analysts project EPS growth of -15.94% annually over the next five years. The latest quarter delivered EPS of -$0.32. The next quarter is forecast at -$0.39. Next year's EPS is expected at -$14.98. Analyst sentiment is bullish. Analyst rating data shows there are 1 Strong Buy ratings, 2 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $52.00 to $37.00. The high target offers 66.93% upside. The low target suggests 18.78% downside. The mean target is $45.67. This offers 46.61% upside. Enliven Therapeutics, Inc. earnings surprise history is frequent misses against expectations. The quarter that ended November 12, 2025, missed forecasts by -24.54%. The prior quarter beat by -7.55%. Over the last six quarters, Apple has recorded several small beats. These include -29.31% in August 13, 2024.

Enliven Therapeutics, Inc. has 59.24 million shares outstanding. The public float is 36.32 million shares, elevated short interest at 12.28% of float. This equals 5.08 million shares. The short ratio is 11.7 days. Institutional investors hold 112.22% of the float. Insiders own 8.88%. RA CAPITAL MANAGEMENT, L.P. holds 2.12 million shares, Leonard Braden Michael has 1.77 million shares and COMMODORE CAPITAL LP has 1.45 million shares. Over the past six months, insider transactions show net selling. They sold 274.33 thousand shares across 25 transactions.

Enliven Therapeutics, Inc. (NASDAQ:ELVN) closed at $31.15 USD, gaining $0.34 (1.10%) from the previous close of $30.81. The stock is currently within 5% of its 52-week high $13.30 and $31.75. With a market capitalization of about $1.86 billion, Enliven Therapeutics, Inc. is classified as a small-cap and shows market-like volatility (beta ~1.06). Key stats such as the average daily volume over the past year has been around 1.10 million shares, in line with its 52-week average. Headquartered in Boulder, CO, Enliven Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Richard A. Fair, the company employs approximately 62 people and listed since March 12, 2020. Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer.

Enliven Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $1.74. This means the shares are trading above this model’s fair value.

Enliven Therapeutics, Inc. trades at a P/E ratio of -16.67, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 3.76 trading at moderately above to book value. The P/FCF stands at -25.9, also below market averages.

Our AI price prediction model suggests that Enliven Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 0.9%, with price expected at $31.43 by April 07, 2026, within a range of $29.95 to $32.73 3-Month Outlook: Projected fall of -6.26%, reaching $29.20 by June 22, 2026, with a range of $27.74 to $30.55. 1-Year Outlook: Projected gain of 5.81%, with price at $32.96 by March 24, 2027, within a range of $31.62 to $34.36.

Enliven Therapeutics, Inc. (NASDAQ:ELVN) shares are up 75.65% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Enliven Therapeutics, Inc. trading at a premium to the broader market with a P/E of -16.67. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $38.80, suggesting 24.56% upside. Our AI forecast model points to short-term strength (0.9% over two weeks), a medium-term fall (-6.26% over three months), and a longer-term gain (5.81% over one year), with expected trading ranges indicating moderate volatility.